

Trogocytosis in Multiple Myeloma

Karieshma Kabani

**A thesis submitted for the degree of
Master of Science (MSc)
Faculty of Science**

2012



**UNIVERSITY OF
TECHNOLOGY SYDNEY**

DECLARATION

I declare that no part of the work described in this thesis has been submitted for any other degree nor has it been submitted as part of the requirements for another degree.

As the author of this thesis, I also certify that the thesis has been written by me, any help that I have received in my research work and the preparation of the thesis has been acknowledged. All due acknowledgement has been made where appropriate.

Karieshma Kabani

DEDICATION

This thesis is dedicated to my family whose love and support encourages me to work hard and do the best I can.

ACKNOWLEDGEMENTS

Thank you to my supervisors Dr Ross Brown, Narelle Woodland and Dr Najah Nassif for their constant support, mentorship, enthusiasm and guidance over the last 4 years. I am grateful for your generosity, encouragement, willingness to listen and experienced advice.

I would like to thank Professor Doug Joshua and Professor Joy Ho for attending the weekly research meetings, though you both have been very busy, I appreciate your expert advice, suggestions, new ideas and directions which have been extremely helpful. Thank you to Dr Phillip Fromm for your friendly advice and for sharing your knowledge and experiences. Thank you to Shihong Yang for your kind help with equipment and method problems and for assisting with cell sorting. Thank you to Dr Louise Cole at the Bosch Institute at University of Sydney for the beautiful images acquired from the confocal microscope.

It has been a wonderful experience working as a research assistant at the Institute of Haematology at Royal Prince Alfred Hospital and for that I would like to thank Dr Ross Brown for giving me a chance. Having little experience, you gave me the opportunity to work with such great people and broaden my skills and knowledge and venture into new areas, for this I am very grateful.

I would also like to thank Chris Coad and the haematology staff for their friendship and advice. Also, many thanks to the blood collectors in the haematology clinic and registrars at RPAH for their friendship and assistance with blood and bone marrow collections. Thank you to the myeloma patients and donors without you this project would not be possible.

I would also like to thank my amazing team of editors, Dr Ross Brown, Narelle Woodland, Dr Najah Nassif and Dr Phillip Fromm, your proof reading skills have truly been invaluable.

I would also like to acknowledge the financial support I received from the Sydney Foundation for Medical Research and Cancer Institute NSW.

Finally I would like to thank my friends and family who have encouraged and supported me in this journey. To my mum, dad and sister your unconditional support, encouragement and love have kept me going and helped me to achieve my goals.

PUBLICATIONS ARISING FROM THE WORK DESCRIBED IN THIS THESIS

A) Publications in peer reviewed journals

Reid S, Yang S, Brown R, **Kabani K**, Aklilu E, Ho PJ, Woodland N, Joshua DE. (2010) Characterisation and relevance of CD138⁺ plasma cells in plasma cell myeloma. *International Journal of Laboratory Haematology* 32:e190-e196.

Brown RD, Spencer A, Ho PJ, Kennedy N, Dolotin M, **Kabani K**, Yang S, Sze D, Aklilu E, Gibson J, Joshua D. (2009) Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. *Leukaemia and Lymphoma* 50:1860-1864.

B) Conference Abstracts/Presentations

Brown R, **Kabani K**, Yang S, Favaloro J, Ho PJ, Gibson J, Fromm P, Hart D, Woodland N, Nassif N, Joshua D. (2011) HLA-G acquired by bone marrow T cells mediates tumour escape in myeloma, oral presentation to be presented at *Haematology society of Australia and New Zealand (HAA), O16*.

Kabani K, Brown R, Yang S, Aklilu E, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2011) HLA-G can be acquired by T cells via trogocytosis and is a clinically relevant immunoregulator in patients with myeloma, poster presented at the 13th International myeloma workshop. *Haematologica* 96 (s1), S38.

Kabani K, Brown R, Yang S, Aklilu E, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2011) Incidence and relevance of trogocytosis in multiple myeloma and other B cell malignancies determined by flow cytometry, poster presented at the 13th international myeloma workshop. *Haematologica* 96 (s1), S38.

Kabani K, Brown R, Yang S, Aklilu E, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2010) Incidence and relevance of trogocytosis in multiple myeloma and other B cell malignancies determined by flow cytometry, poster presented at the *Australasian Flow Cytometry group (AFCG) p86*.

Brown R, **Kabani K**, Yang S, Aklilu E, Ho PJ, Gibson J, Joshua D. (2010) HLA-G and CD86 expression on malignant plasma cells convey a poor prognosis and immunoregulate T cells in patients with myeloma, oral presentation at the American Society of Haematology. *Blood 116:983*.

Brown R, Li J, Yang S, **Kabani K**, Aklilu E, Ho PJ, Gibson J, Kaplan W, Joshua D. (2010) The anergic and expanded cytotoxic T cell clones in patients with plasma cell dyscrasias, oral presentation at *Haematology society of Australia and New Zealand (HAA) A90*.

Kabani K, Brown R, Yang S, Aklilu E, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2010) Incidence and relevance of trogocytosis in multiple myeloma and other B cell malignancies, oral presentation at *Haematology society of Australia and New Zealand Proc (HAA), A93*.

Kabani K, Brown R, Lyons A, Yang S, Aklilu E, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2010) Immunomodulatory effects of HLA-G in multiple myeloma, oral presentation at *Haematology society of Australia and New Zealand (HAA), A95*.

Brown R, Li J, Sze D, Yang S, **Kabani K**, Aklilu E, Ho PJ, Gibson J, Cowley M, Kaplan W, Loh YS, Yamagishi T, Joshua D. (2010) Flow detection and analysis of the anergic and expanded cytotoxic T cell clones in patients with plasma cell dyscrasias, poster presented at the *Australasian Flow Cytometry group (AFCG) p63*.

Yang S, Brown R, Reid S, **Kabani K**, Aklilu E, Ho PJ, Woodland N, Joshua D. (2009). Characterisation of CD138⁺ plasma cells in multiple myeloma, poster presented at the *Australasian Flow Cytometry group (AFCG), p66*.

Lyons A, Brown R, **Kabani K**, Yang S, Aklilu E, Joshua D. (2009) HLA-G expression and relevance in myeloma, poster presented at *Haematology society of Australia and New Zealand (HAA)*, pA359.

Kabani K, Brown R, Lyons A, Woodland N, Nassif N. (2009) HLA-G in Plasma Cell Myeloma, oral presentation at the *Scientific Research Meeting (RNSH/UTS/USyd/KIMR)*, O2.

Yang S, Brown RD, Sze DM, **Kabani K**, Aklilu E, Ho PJ, Joshua D (2008) Detection, phenotype and prognostic significance of T cell clones in multiple myeloma. *Proc AFCG 54*.

Brown RD, **Kabani K**, Aklilu E, Sze D, Ho PJ, Gibson J, Joshua DE. (2008) Trogocytosis in Multiple Myeloma. *Blood* 112 S1: 594.

Brown R, Yang S, **Kabani K**, Aklilu E, Sze D, Mo S, Gibson J, Ho PJ, Joshua D. (2008) T Cell Control of Monoclonal Gammopathies: Further Evidence from Waldenstrom's Macroglobulinaemia, poster presented at the *Haematology society of Australia and New Zealand (HAA)*. pA152.

Kabani K, Brown R, Yang S, Aklilu E, Sze D, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2008) Trogocytosis of biotinylated protein membrane from myeloma cells, oral presentation at the *Scientific Research Meeting (RNSH/UTS/USyd/KIMR)*.

Kabani K, Brown R, Yang S, Aklilu E, Sze D, Woodland N, Nassif N, Ho PJ, Gibson J, Joshua D. (2008) Trogocytosis in Multiple Myeloma, poster presented at *Haematology society of Australia and New Zealand (HAA)*, pA355.

Brown R, Spencer A, Kennedy N, Dolotin M, **Kabani K**, Ho PJ, Sze DM, Gibson J, Joshua D. (2007) The presence of T cell clones in patients with multiple myeloma is increased after thalidomide maintenance therapy (ALLG-MM6) and is associated with an improved survival, oral presentation at *Haematology society of Australia and New Zealand (HAA)*, A205.

Table of Contents

TABLE OF CONTENTS	i
LIST OF FIGURES	vi
LIST OF TABLES	ix
ABBREVIATIONS	x
ABSTRACT	xiii
CHAPTER ONE	1
1. INTRODUCTION	2
1.1 Multiple Myeloma: an Introduction	2
1.1.1 Plasma cells.....	3
1.1.2 Bone marrow microenvironment and angiogenesis.....	4
1.1.3 Epidemiology of myeloma.....	4
1.1.4 Aetiology of myeloma	5
1.1.5 Classification of the monoclonal gammopathies and myeloma	5
1.1.6 Diagnosis of multiple myeloma	7
1.1.7 Staging of multiple myeloma.....	12
1.1.8 Prognostic indicators in multiple myeloma	14
1.1.9 Multiple myeloma treatment.....	14
1.2 The Immune System.....	16
1.2.1 The innate immune system	16
1.2.2 The adaptive immune system.....	17
1.2.3 B cells.....	18
1.2.4 T cells.....	18
1.2.5 T cell activation.....	18
1.2.6 T cell clones	19
1.2.7 Formation of an immunological synapse.....	20

1.2.8	Antigen acquisition and mechanisms of molecular transfer	23
1.3	Trogocytosis	26
1.3.1	Physiological and functional significance of trogocytosis in the immune response	28
1.3.2	Involvement of co-stimulatory molecules	30
1.3.3	Trogocytosis and T cell activation	36
1.3.4	T cells as non-professional APCs	37
1.4	The Non-Classical HLA-G Molecule	37
1.4.1	HLA-G isoforms	38
1.4.2	Functional significance of HLA-G	40
1.4.3	Physiological role of HLA-G	42
1.4.4	HLA-G expression and malignancies	43
1.4.5	HLA-G and inflammatory diseases	46
1.4.6	Expression of HLA-G by antigen presenting cells	46
1.4.7	HLA-G and trogocytosis	48
1.4.8	HLA-G and a new subset of regulatory T cells	48
1.5	Project Rationale	51
1.6	Project Objectives	51
CHAPTER TWO		53
2.	MATERIALS AND METHODS	54
2.1	Materials	54
2.1.1	Study samples	54
2.1.2	Bone marrow collection	54
2.1.3	Peripheral blood collection	54
2.1.4	Complete culture medium	55
2.1.5	Human myeloma and T cell lines	55

2.1.6	Reagents	55
2.2	Methods	58
2.2.1	Cell preparation	58
2.2.2	Cell culture techniques	59
2.2.3	Cell surface staining and Flow cytometry	60
2.2.4	<i>In vitro</i> model of trogocytosis	60
2.2.5	Flow sorting	62
2.2.6	Culture and stimulation of PBMCs	62
2.2.7	CFSE labelling of HLA-G ^{neg} T cells and suppression assay	63
2.2.8	Statistical analysis	63
CHAPTER THREE		64
3.	EVIDENCE OF TROGOCYTOSIS	65
3.1	Introduction	65
3.2	Results	66
3.2.1	Biotinylation of plasma cells	66
3.2.2	Optimisation of the biotinylation assay	66
3.2.3	Evidence of trogocytosis detected by confocal microscopy	70
3.2.4	Evidence for trogocytosis by flow cytometry	70
3.2.5	Trogocytosis is independent of T cell engagement and HLA matching	73
3.2.6	Trogocytosis is predominately uni-directional	78
3.2.7	Trogocytosis in multiple myeloma	80
3.2.8	Trogocytosis in other B cell malignancies	80
CHAPTER FOUR		86
4.	B7 FAMILY MOLECULES AT THE IMMUNOLOGICAL SYNAPSE	87
4.1	Introduction	87

4.2	Results	88
4.2.1	Immunophenotype of myeloma cell lines	88
4.2.2	Immunological synapse molecules on plasma cells of patients.....	91
4.2.3	Immunological synapse molecules on T cells of patients.....	91
4.2.4	CD86 expression on T cells and malignant plasma cells in the same bone marrow sample.....	96
4.2.5	CD86 expression on peripheral blood T cells and malignant plasma cells from myeloma patients	96
4.2.6	Acquisition of CD86 by T cells	100
4.2.7	Inhibition of T cell proliferation	100
CHAPTER FIVE		105
5.	HLA-G EXPRESSION.....	106
5.1	Introduction	106
5.2	Results	107
5.2.1	HLA-G expression on plasma cells of multiple myeloma patients	107
5.2.2	HLA-G expression is not related to stage of myeloma.....	110
5.2.3	Correlation of HLA-G expression and overall survival in multiple myeloma	110
5.2.4	Expression of HLA-G on T cells of myeloma patients and normal individuals	113
5.2.5	HLA-G expression on peripheral blood T cells and bone marrow plasma cells from the same patient	113
5.2.6	HLA-G expression on bone marrow T cells and bone marrow plasma cells from the same sample.....	113
5.2.7	HLA-G acquisition by trogocytosis	118
5.2.8	HLA-G ^{pos} T cells: a new subset of regulatory T cells.....	118

CHAPTER SIX	122
6. DISCUSSION.....	123
6.1 Trogocytosis is a Common Finding in MM	123
6.2 Co-stimulatory Molecules Transferred by Trogocytosis	125
6.3 The Immunomodulatory Molecule: HLA-G	128
6.4 Conclusion.....	130
6.5 Future Directions	130
REFERENCES	132

List of Figures

Figure 1-1: Bone marrow film from a multiple myeloma patient, showing an abundance of plasma cells	9
Figure 1-2: X rays of bones and skull from myeloma patients	10
Figure 1-3: Electrophoretic analysis of monoclonal proteins from a myeloma patient	11
Figure 1-4: Formation of an immunological synapse	21
Figure 1-5: Molecular transfer between antigen presenting cells and T cells	25
Figure 1-6: Co-stimulatory molecules and receptors found on APCs and T cells.....	31
Figure 1-7: Alternative splicing of the primary HLA-G transcript results in seven HLA-G isoforms	39
Figure 1-8: Schematic representation of the inhibitory effects of membrane-bound and soluble HLA-G on various effector cells	41
Figure 3-1: Biotinylation of a plasma cell line	67
Figure 3-2: Transfer of biotin from plasma cells to mononuclear cells.....	68
Figure 3-3: Transfer of biotin from a plasma cell line, OPM2 to CD3 ⁺ T cells	69
Figure 3-4: Visualisation of trogocytosis by confocal microscopy	71
Figure 3-5: Flow cytometry detection of biotinylated membrane fragments.	72
Figure 3-6: Biotin transfer from biotinylated plasma cells to the TCR negative Jurkat cell line.....	74
Figure 3-7: Biotin transfer from flow sorted bone marrow plasma cells to autologous T cells.....	75
Figure 3-8: Biotin transfer from flow sorted bone marrow plasma cells to allogeneic T cells	76
Figure 3-9: HLA compatibility is not required for trogocytosis.....	77
Figure 3-10: The directionality of biotinylated membrane fragment transfer	79
Figure 3-11: Biotin expression on a plasma cell line, U266 and peripheral blood mononuclear cells following co-culture.....	81
Figure 3-12: Biotin transfer to peripheral blood mononuclear cells from normal controls compared to myeloma patients	82
Figure 3-13: Expression of biotin on T cells following culture with bone marrow B cells from a WM patient	83

Figure 3-14: Biotin expression on T cells following culture with B cells from a CLL patient.....	84
Figure 3-15: Trogocytosis is common in myeloma compared to other B cell malignancies	85
Figure 4-1: Immunophenotype of plasma cells	89
Figure 4-2: Expression of co-stimulatory molecules and counter-receptors on bone marrow plasma cells from myeloma patients	92
Figure 4-3: Flow cytometric analysis of B7 family marker expression on CD3 positive cells	93
Figure 4-4: Expression of co-stimulatory molecules and counter-receptors on peripheral blood T cells from myeloma patients and normal control individuals	94
Figure 4-5: Expression of co-stimulatory molecules and counter-receptors on T cell subsets	95
Figure 4-6: Representative flow plots of CD86 expression on bone marrow plasma cells and bone marrow T cells	97
Figure 4-7: Correlation between CD86 expression on T cells and malignant plasma cells in bone marrow samples from patients with myeloma.....	98
Figure 4-8: Expression of CD86 on bone marrow plasma cells and peripheral blood T cells	99
Figure 4-9: Correlation between CD86 expression on T cells and malignant plasma cells in bone marrow samples from patients with myeloma.....	101
Figure 4-10: Representative flow plots showing T cell proliferation by CD86 expressing T cells.....	102
Figure 4-11: Representative flow plots showing T cell proliferation by CD86 expressing plasma cells.....	103
Figure 4-12: Inhibition of proliferation by CD86 expressing cells.....	104
Figure 5-1: Representative flow plots of HLA-G expression on bone marrow plasma cells of multiple myeloma patients	108
Figure 5-2: HLA-G expression on bone marrow plasma cells varies between patients	109
Figure 5-3: Correlation of HLA-G expression and stage of multiple myeloma	111
Figure 5-4: Correlation of HLA-G expression and overall survival in myeloma.....	112
Figure 5-5: HLA-G expression on T cells of myeloma patients and age-matched control individuals	114

Figure 5-6: HLA-G expression on bone marrow plasma cells and peripheral blood T cells within individual patients	115
Figure 5-7: Representative flow plots of HLA-G expression on bone marrow plasma cells and T cells from the same patient.....	116
Figure 5-8: HLA-G expression on bone marrow plasma cells and T cells within individual patients.....	117
Figure 5-9: HLA-G expression on T cells following trogocytosis	119
Figure 5-10: Representative flow plots of T cell proliferation and inhibition of proliferation.....	120
Figure 5-11: Inhibition of proliferation of HLA-G ^{neg} T cells by HLA-G expressing cells	121
Figure 6-1: Transfer of CD86 to T cells can regulate tumour escape.....	126

List of Tables

Table 1-1: Characteristics of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and multiple myeloma	6
Table 1-2: Clinical parameters for multiple myeloma staging by the Durie-Salmon staging system.....	13
Table 1-3: Clinical parameters for multiple myeloma staging by the International Staging System.....	13
Table 1-4: The B7 family molecules and co-receptors	32
Table 2-1: Reagents and solutions used in multiple experiments.....	56
Table 2-2: Antibodies used for flow cytometry and their associated incubation time for labelling.....	57
Table 4-1: Expression of surface markers on plasma cell lines.....	90

Abbreviations

ALL	Acute lymphoblastic leukemia
AML	Acute myeloid leukemia
APCs	Antigen presenting cells
APC	Allophycocyanin
ASCT	Autologous stem-cell transplantation
ATCC	American type culture collection
BCR	B cell receptor
BM	Bone marrow
CD	Cluster differentiation
CFSE	Carboxyfluorescein succinimidyl ester
CLL	Chronic lymphocytic leukemia
CTL	Cytotoxic T lymphocyte
CTLA-4	Cytolytic T lymphocyte-associated antigen 4
Cy5.5	Cyanine 5.5
Cy7	Cyanine 7
DC	Dendritic cell
DMSO	Dimethyl sulfoxide
EDTA	Ethylenediamine tetraacetic acid
EFS	Event free survival
FACS	Fluorescent-activated cell sorting
FCS	Foetal calf serum
FGF	Fibroblast growth factor
FISH	Fluorescent <i>in situ</i> hybridisation
FITC	Fluorescein isothiocyanate
FLC	Free light chains
FoxP3	Forkhead transcription factor 3
FSC	Forward scatter
GM-CSF	Granulocyte macrophage – colony stimulating factor
Hb	Haemoglobin
HLA	Human leukocyte antigen
IFN	Interferon

Ig	Immunoglobulin
IL	Interleukin
ILT	Immunoglobulin-like transcript receptors
IS	Immunological synapse
ISS	International staging system
KIR	Killer Ig-like receptors
M-protein	Monoclonal protein
MGUS	Monoclonal gammopathy of undetermined significance
MHC	Major histocompatibility complex
MM	Multiple myeloma
MRI	Magnetic resonance imaging
MS	Multiple sclerosis
NF- κ B	Nuclear Factor-kappa B
NHL	Non-Hodgkin's lymphoma
NK	Natural killer
OS	Overall survival
PB	Peripheral blood
PBMC	Peripheral blood mononuclear cells
PBS	Phosphate buffered saline
PC	Plasma cell
PCLI	Plasma cell labelling index
PCR	Polymerase chain reaction
PerCP	Peridinin chlorophyll protein
PFS	Progression free survival
PHA	Phytohemagglutinin
pMHC	peptide MHC
R-PE	R-phycoerythrin
rpm	Revolutions per minute
RPMI	Rosewell Park Memorial Institute
RT	Room temperature
Rt-PCR	Reverse transcription polymerase chain reaction
SMM	Smoldering multiple myeloma
SSC	Side scatter
TCR	T cell receptor

TGF	Tumour growth factor
TNF	Tumour necrosis factor
VEGF	Vascular endothelial growth factor
WBC	White blood cells
WM	Walsendrom macroglobulinemia
β_2 M	Beta-2-microglobulin

Abstract

The term trogocytosis is used to describe the fast, cell-to-cell contact-dependent transfer of membrane proteins between cells, with T and B-lymphocytes, natural killer (NK) cells, antigen presenting cells (APC) and tumour cells being the most widely studied. This study aimed to: (1) identify the extent of trogocytosis in patients with multiple myeloma (MM), a malignancy of bone marrow plasma cells, compared with the other B cell malignancies, (2) to identify some of the molecules involved with trogocytosis in these patients and then (3) determine if cells that had acquired molecules had altered function.

An *in vitro* model of trogocytosis was established in which plasma cell lines and flow-sorted bone marrow plasma cells (CD38⁺⁺) of patients with MM (n=11) or the malignant B cells from patients with chronic lymphocytic leukaemia (CLL) (CD5⁺CD19⁺) (n=4) and Waldenstrom macroglobulinaemia (WM) (CD19⁺) were biotinylated and then cultured with either patient or normal mononuclear cells. The acquisition of biotinylated membrane proteins was determined by flow cytometry and confocal microscopy. Screening for potential molecules involved suggested that CD86 and HLA-G were likely candidates for trogocytosis. CD86 is a co-stimulatory molecule at the immune synapse and HLA-G is a non-classical MHC class I molecule which prevents antigen-specific cytolysis by cytotoxic T lymphocytes (CTLs), inhibits the function of circulating NK cells and prevents proliferation of allogeneic CD4⁺ T cells. These observations have led to the hypothesis that expression of HLA-G may aid in the escape of tumours from immune surveillance.

T cells acquired significantly more biotinylated proteins (mean=13.55%) than B cells (mean=2.43%; t=2.80; p<0.05) or NK cells (mean=3.15%; t=2.57; p<0.05). There was no significant difference between levels of biotin transferred to T cells from either plasma cell lines or primary plasma cells and acquisition was the same with autologous and allogeneic T cells. Significantly more trogocytosis was observed in myeloma patients than other B cell malignancies (n=5) as <1% T cells acquired membrane fragments when cultured with malignant B cells from patients with CLL or WM (t =3.86; p<0.05). Upon culture with biotinylated CD3⁺ flow-sorted normal T

cells, approximately 2% of CD38⁺⁺ plasma cells acquired membrane fragments, suggesting that in patients with myeloma, trogocytosis was predominantly unidirectional.

Although HLA-G expression was found on 0.02 – 0.56% of normal T cells (mean =0.23%), 20% of MM patients (11 of 56) demonstrated a level of HLA-G⁺ CD3⁺ T cells above the normal range. Addition of flow-sorted CD3⁺ HLA-G^{pos} T cells led to a reduction in the proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labelled CD3⁺ HLA-G^{neg} T cells stimulated with anti-CD3/CD28 beads and this inhibition was greater than the inhibition due to CD38⁺⁺ HLA-G^{pos} plasma cells (t=2.64; p=0.046). The CD3⁺ HLA-G^{pos} T cells acquired inhibitory function but were not natural T regulatory cells as they were CD25^{neg}. Overall survival was significantly worse for the 11/46 patients with HLA-G^{pos} plasma cells ($\chi^2=12.4$; p<0.0004).

Flow cytometric analysis of CD38⁺⁺ bone marrow plasma cells from MM patients showed varied HLA-G expression ranging from 0.2% to 96% (n=46). The clinical relevance of HLA-G^{pos} plasma cells was demonstrated by a significant reduction in overall survival (n= 46; $\chi^2= 12.4$; p<0.004). CD86 expression on T cells of myeloma patients (n=98) ranged from 0 – 30% (normals = 0 – 2.7%; n=10). T cells from myeloma patients (n=7), when co-cultured with CD86 expressing plasma cells, were found to acquire significantly (p<0.0001) higher levels of CD86.

This study reports several new findings. It has shown that trogocytosis is more common in multiple myeloma than other B cell malignancies, is primarily unidirectional, HLA independent and T cells are more likely to be involved than other lymphocytes. T cells which acquire tumour antigens may have altered function and it has been demonstrated that HLA-G^{pos} T cells form a new subset of acquired regulatory T cells that inhibit the proliferation of HLA-G^{neg} T cells and therefore protect MM cells against the host's immune defences.